AR
ARX.AU Aroa Biosurgery Ltd
- Market cap
- AUD 193M
- P/E
- 55.0x
- P/B
- 2.33x
- ROE
- 5.0%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the fiscal year ending Mar 2026.
Is ARX.AU undervalued?
Graham numberARX.AU trades 138.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aroa Biosurgery Ltd fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (5.0%), below 10%.
ROA 1/1
Return on assets (4.1%) is above the industry median (-16.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (213.8%) is above the industry median (23.6%).
Revenue Growth 2/2
Revenue grew 15.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (6.4%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 10.4x against interest expense, well covered.
PE vs Market 0/1
PE (55.0x) is above the market median (15.0x).
PE vs Industry 0/1
PE (55.0x) is above the industry median (9.9x).
PBV 0/1
Price to book (2.3x) is above the industry median (1.5x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 128.1, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Aroa Biosurgery Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symp…
Full company profileAroa Biosurgery Ltd financial statements
Aroa Biosurgery Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 9.66M | 21.8M | 24.3M | 20.5M | 36.9M | 59.3M | 63.4M | 77.0M | 92.3M |
| Gross Profit | 0.00 | 4.21M | 13.7M | 17.5M | 14.3M | 28.2M | 50.1M | 54.1M | 66.0M | 79.6M |
| Operating Income | -843K | -2.24M | -179K | -2.83M | -10.3M | -6.98M | -2.91M | -9.79M | -8.13M | 4.36M |
| EBITDA | - | -1.56M | 1.65M | -219K | -7.45M | -3.75M | 594K | -7.36M | 2.66M | 9.03M |
| Net Income | -723K | -1.18M | 896K | -5.66M | -17.6M | -7.79M | -371K | -9.75M | -3.47M | 4.16M |
| EPS | - | 0.00 | 0.00 | -0.02 | -0.06 | -0.02 | 0.00 | -0.03 | -0.01 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 6.52M | 14.3M | 38.0M | 44.5M | 73.1M | 105M | 109M | 102M | 98.9M | 100M |
| Total Liabilities | 235K | 12.5M | 26.4M | 19.7M | 19.4M | 11.3M | 13.7M | 14.8M | 14.3M | 17.7M |
| Shareholders' Equity | 6.28M | 1.77M | 11.5M | 62.9M | 53.7M | 93.4M | 95.4M | 87.1M | 84.6M | 82.7M |
| Cash & Short-term Investments | 800K | 3.65M | 4.29M | 42.4M | 33.9M | 53.4M | 43.0M | 27.7M | 20.1M | 22.6M |
| Total Debt | - | 1.52M | 1.09M | 10.8M | 15.4M | 5.83M | 7.07M | 6.82M | 5.83M | 5.31M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -737K | -2.80M | -6.54K | 1.58M | -5.01M | -10.7M | -3.53M | -6.76M | -2.33M | 9.37M |
| Capital Expenditure | 40.9K | 1.55M | 1.53M | 1.78M | 1.38M | 4.53M | 7.12M | 3.23M | 3.36M | 985K |
| Free Cash Flow | - | -4.36M | -1.54M | -200K | -1.38M | -15.4M | -10.7M | -10.00M | -5.69M | 8.39M |
| Ratios | ||||||||||
| ROE | -11.5% | -66.7% | 7.8% | -9.0% | -32.8% | -8.3% | -0.4% | -11.2% | -4.1% | 5.0% |
| ROA | -11.1% | -8.2% | 2.4% | -12.7% | -24.1% | -7.4% | -0.3% | -9.6% | -3.5% | 4.1% |
| Net Profit Margin | - | -12.2% | 4.1% | -23.3% | -86.0% | -21.1% | -0.6% | -15.4% | -4.5% | 4.5% |
| Debt to Equity | - | 0.86x | 0.09x | 0.17x | 0.29x | 0.06x | 0.07x | 0.08x | 0.07x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aroa Biosurgery Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | NZD 0.08 | 0.00 | - |
| 2021 | NZD 18.2M | 0.06 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 1, 2018.
Who owns Aroa Biosurgery Ltd
- Insiders 27.29%
- Institutions 33.99%
- Public & others 38.72%
- Shares outstanding 351M
- Free float 260M
Aroa Biosurgery Ltd company profile
- Company name
- Aroa Biosurgery Ltd
- Ticker
- ARX.AU
- ISIN
- NZARXE0001S1
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Metals & Mining
- Fiscal year end
- March
- Address
- 64 Richard Pearse Drive, Auckland, New Zealand, 2022
- Phone
- 64 9 869 3035
- Website
- aroa.com
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Aroa Biosurgery Ltd management
9- Dr. Brian Ward B.V.Sc, MBA(dist)Founder, CEO, MD & Executive Director
- Mr. James Agnew BCom, LLBCFO & Joint Company Secretary
- Mr. Rod Stanley M.Sc.Chief Operating Officer
- Ms. Yasmin Winchester B.Sc.Chief of Technical Operations
- Dr. Barnaby C.H. May Ph.D.Chief Scientific Officer
- Mr. Michael LynskeyChief Commercial Officer
- Ms. Tracy Weimar BA, MBAJoint Company Secretary
- Mr. Adam Young Ph.D.Vice President of Medical Affairs
- Sarah ToraMedia Executive